Cargando…
Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial
BACKGROUND: Fatigue is a common symptom in people with multiple sclerosis (pwMS) that significantly impairs quality of life. Bright light therapy may be a cheap treatment option with little to no adverse events. OBJECTIVES: To evaluate the effectiveness of bright light therapy as a treatment option...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647309/ https://www.ncbi.nlm.nih.gov/pubmed/36387033 http://dx.doi.org/10.1177/20552173221133262 |
_version_ | 1784827360248332288 |
---|---|
author | Voggenberger, Lisa Böck, Marion Moser, Doris Lorbeer, Gudrun Altmann, Patrick Leutmezer, Fritz Berger, Thomas Seidel, Stefan |
author_facet | Voggenberger, Lisa Böck, Marion Moser, Doris Lorbeer, Gudrun Altmann, Patrick Leutmezer, Fritz Berger, Thomas Seidel, Stefan |
author_sort | Voggenberger, Lisa |
collection | PubMed |
description | BACKGROUND: Fatigue is a common symptom in people with multiple sclerosis (pwMS) that significantly impairs quality of life. Bright light therapy may be a cheap treatment option with little to no adverse events. OBJECTIVES: To evaluate the effectiveness of bright light therapy as a treatment option for MS-related fatigue. METHODS: This was randomized sham-controlled trial including 26 pwMS with a Fatigue Severity Scale (FSS) Score ≥36. Participants were assigned to receive either bright white light therapy (n = 13) or dim red light (sham-intervention; n = 13). Participants used the respective intervention for 30 min each morning for two weeks, followed by a two-week washout period. The primary endpoint was the difference in FSS scores following light treatment as calculated by analysis of covariance. RESULTS: There was no significant difference in FSS (F(1,23) = 2.39, p = .136, partial ⴄ(2) = .094). However, FSS scores generally improved over the course of the study in a clinically relevant manner. CONCLUSION: Bright light therapy decreased FSS scores over the course of this study. However, this effect was not significant in comparison to a sham intervention. |
format | Online Article Text |
id | pubmed-9647309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-96473092022-11-15 Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial Voggenberger, Lisa Böck, Marion Moser, Doris Lorbeer, Gudrun Altmann, Patrick Leutmezer, Fritz Berger, Thomas Seidel, Stefan Mult Scler J Exp Transl Clin Original Research Article BACKGROUND: Fatigue is a common symptom in people with multiple sclerosis (pwMS) that significantly impairs quality of life. Bright light therapy may be a cheap treatment option with little to no adverse events. OBJECTIVES: To evaluate the effectiveness of bright light therapy as a treatment option for MS-related fatigue. METHODS: This was randomized sham-controlled trial including 26 pwMS with a Fatigue Severity Scale (FSS) Score ≥36. Participants were assigned to receive either bright white light therapy (n = 13) or dim red light (sham-intervention; n = 13). Participants used the respective intervention for 30 min each morning for two weeks, followed by a two-week washout period. The primary endpoint was the difference in FSS scores following light treatment as calculated by analysis of covariance. RESULTS: There was no significant difference in FSS (F(1,23) = 2.39, p = .136, partial ⴄ(2) = .094). However, FSS scores generally improved over the course of the study in a clinically relevant manner. CONCLUSION: Bright light therapy decreased FSS scores over the course of this study. However, this effect was not significant in comparison to a sham intervention. SAGE Publications 2022-11-07 /pmc/articles/PMC9647309/ /pubmed/36387033 http://dx.doi.org/10.1177/20552173221133262 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Article Voggenberger, Lisa Böck, Marion Moser, Doris Lorbeer, Gudrun Altmann, Patrick Leutmezer, Fritz Berger, Thomas Seidel, Stefan Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial |
title | Bright light therapy as a non-pharmacological treatment option for
multiple sclerosis-related fatigue: A randomized sham-controlled
trial |
title_full | Bright light therapy as a non-pharmacological treatment option for
multiple sclerosis-related fatigue: A randomized sham-controlled
trial |
title_fullStr | Bright light therapy as a non-pharmacological treatment option for
multiple sclerosis-related fatigue: A randomized sham-controlled
trial |
title_full_unstemmed | Bright light therapy as a non-pharmacological treatment option for
multiple sclerosis-related fatigue: A randomized sham-controlled
trial |
title_short | Bright light therapy as a non-pharmacological treatment option for
multiple sclerosis-related fatigue: A randomized sham-controlled
trial |
title_sort | bright light therapy as a non-pharmacological treatment option for
multiple sclerosis-related fatigue: a randomized sham-controlled
trial |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647309/ https://www.ncbi.nlm.nih.gov/pubmed/36387033 http://dx.doi.org/10.1177/20552173221133262 |
work_keys_str_mv | AT voggenbergerlisa brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial AT bockmarion brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial AT moserdoris brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial AT lorbeergudrun brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial AT altmannpatrick brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial AT leutmezerfritz brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial AT bergerthomas brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial AT seidelstefan brightlighttherapyasanonpharmacologicaltreatmentoptionformultiplesclerosisrelatedfatiguearandomizedshamcontrolledtrial |